asciminib
novartis
['asciminib', 'leusm', 'cml']
frontline asciminib produced an early molecular response rate of 92% in patients with chronic phase cml. #ash22 #leusm #cml 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.